Therefore, we consider the suggestion to integrate CKD into economic evaluations to be valid and highly significant from both clinical and policy perspectives.
← all excerpts
Incorporating chronic kidney disease into the cost-effectiveness of MASLD treatment: Correspondence to letter to the editor on "Evaluating treatment response thresholds for cost-effective treatment in metabolic dysfunction-associated steatotic liver disease".
1
—
—